study used 20 mg of atorvastatin, which is about ten times its median effective dose (ED50) 1 and contrasts with the doses of enalapril and hydrochlorothiazide, which were both used close to their respective ED50. 2 The aspirin dose used was about three times its ED50. The high statin dose might have contributed to the nearly significant 26% increase in non-cardiovascular mortality because of dose-related, potentially serious adverse effects of statins. These adverse effects include diabetes, cerebral haemorrhage, renal impairment, liver dysfunction, and rhabdomyolysis. 3, 4 This concerning finding might benefit from further study, although cause of death could be difficult to ascertain reliably, even in patients who are closely monitored. Risk-benefit considerations might favour smaller doses in primary prevention than in secondary prevention. Statins have been repeatedly shown to reduce total mortality, but not to a greater extent above an equivalent of about 4 mg of atorvastatin. 5 We suggest that little justification exists for combining a disproportionately high dose of statin with the other drugs, each of which can reduce clinical events by around 20%.
We declare no competing interests. each country were not available. For these studies, we dichotomised the different countries according to their overall proportion of the population vaccinated, on the basis of the number of cohorts vaccinated (single-cohort or multi-cohort) and the vaccination coverage of the routine cohort. For our future work and for the global surveillance of the worldwide impact of HPV vaccination, especially con sidering WHO's call for action to eliminate cervical cancer, it would be crucial to improve the quality and exhaustiveness of vaccination coverage information.
We declare no competing interests. with multi-cohort vaccination than with single-cohort vaccination or low vaccination coverage, and similar longterm effects for multi-cohort and singlecohort vaccination strategies. 2,3 In a previous study, 2 we showed that 5 years after the start of vaccination, Australia's catch-up programme contributed to more than half of the observed reductions in anogenital warts and, in the long term, the predicted declines were the same with or without catch-up. Because of HPV vaccine supply shortages, it is currently impossible for all countries introducing HPV vaccination to implement multicohort strategies. Alternative recommendations are being considered by WHO. One option is to routinely vaccinate girls at an age closer to sexual debut (13-14 years), then switching back to a younger age when supply constraints are alleviated. Alternatively, extended schedules can be introduced in which a first dose is given at 9 years of age and a second dose is given 3-5 years later (with a temporary catch-up of vaccination at age 13-14 years). 4 These strategies require fewer vaccine doses during the first years of the programmes than would be required with multi-cohort vaccinatio n of girls aged 9-14 years, but maintain many of the advantages of multi-cohort vaccination.
Sasieni and Cuzick highlighted the important association between the vaccine effect and the proportion of the population vaccinated, and suggested a method using cohort-specific vaccination cov erage to esti mate vaccine efficacy. In our study, 1 cohortspecific vaccination coverage was available only for studies examining the effect of HPV vaccination on HPV infections. For these studies, the method suggested by Sasieni and Cuzick would be applicable and, as they showed, would decrease heterogeneity in our results and produce high vaccine efficacy estimates. However, for most studies included in our meta-analysis, the precise vaccination coverage for each birth cohort, each year, and
Polypill for prevention of cardiovascular diseases
The interesting 5-year study by Gholamreza Roshandel and colleagues 1 showed substantial reductions in cardiovascular morbidity with combination pharmacotherapy including antihypertensive, statin, and antithrombotic drugs, but showed no net effect on total mortality. Their the aspirin and statin components of the polypill.
Third, approximately 50% of the study population had a pre-existing diagnosis of hypertension. Despite that, the reported mean systolic blood pressure was 128-134 mm Hg for both groups and was well controlled to begin with. Adding low-dose enalapril and hydrochlorothiazide would be unlikely to reduce adverse cardiovascular outcomes at followup (no significant difference in blood pressure was shown between the treatment and placebo groups), which supports the notion that the main effect was probably due to statin and aspirin.
Finally, the adherence of participants to lifestyle interventions was not reported or measured in either the intervention group or the placebo group, which could have affected the results if there were significant differences between them. In view of these issues, and the evidence from the aspirin primary prevention trials, the use of the polypill strategy, which seems promising and easily applicable, still requires more data before recommending it for the general population. Targeting specific risk factors and tailoring therapy according to precise risk estimates in individual patients seems more judicious in this era of precision medicine.
We declare no competing interests. We read with interest the Article by Gholamreza Roshandel and colleagues 1 on the effectiveness of the polypill, which showed significant reduction in major cardiovascular events in the polypill group compared with the placebo group. Nonetheless, clinicians must be careful when interpreting these findings. First, the proportion of patients with gastrointestinal bleeding in this study was similar in the polypill (0·4%) and placebo (0·3%) groups. However, the proportion of patients with gastrointestinal bleeding in the ARRIVE 2 trial was 0·97% and in the ASCEND 3 trial was 1·8%. Both these trials investigated the use of aspirin as a primary prevention strategy and excluded patients at a high risk of bleeding. This raises questions about whether patients in the study by Roshandel and colleagues 1 complied with the polypill prescription and whether gastrointestinal bleeding was underdiagnosed in the intervention group.
Second, more than 50% of the study participants had total cholesterol of more than 198 mg/dL and mean LDL cholesterol of 117 mg/dL. 1 The adjusted hazard ratio (HR) for major cardiovascular events in the polypill group was 0·66 (95% CI 0·55-0·80). 1 In the JUPITER trial, 4 participants had a mean LDL cholesterol of less than 130 mg/dL and the HR for major cardiovascular events was 0·48 (0·33-0·68) in the rosuvastatin group compared with the placebo group. Moreover, the meta-analysis by Zheng and Roddick 5 showed an HR of 0·89 (0·84-0·95) for major cardiovascular events with aspirin use in primary prevention. Hence, the effects on these events, including cardiovascular mortality, seem to be mostly (if not completely) related to
Authors' reply
We thank Simon Dimmitt and Hans Stampfer for their interest in our study of the effectiveness of a fourcomponent polypill for the prevention of cardiovascular diseases. 1 In clinical prac tice, atorvastatin doses range from 10 mg to 80 mg daily, and 20 mg per day is not considered a high dose. We tested the safety and efficacy of 20 mg atorvastatin in our pilot phase study 2 before using this dose in the main trial. Statins have a very good safety profile: placebo-controlled random ised trials have clearly shown that only a small proportion of adverse events thought to be attributed to statin therapy in clinical practice are actually caused by the statin, 3 and these drugs have been shown to decrease overall mortality in several long-term randomised trials. 3 In our study, too, the adjusted hazard ratio for overall mortality was 0·93 (95% CI 0·77-1·11).
We also thank Osama Dasa and Mohammed Ruzieh for their interest in our study. Low proportions of patients with gastrointestinal bleeding raises the possibility of either underdiagnosis or low compliance in the intervention group of our study. The trial included five gastroenterologists on its research team, excluded patients at medium and high risk of bleeding, and provided study participants with free access to a gastrointestinal endoscopy clinic at the study centre in Gonbad City, Iran. The team was especially interested in looking for gastrointestinal bleeding in all participants. Therefore, it is very unlikely that there was underdiagnosis of gastrointestinal bleeding in the intervention group. Compliance was measured using pill
